KRAS and cancer: The aromatic nitrogen (N) of binimetinib forms a stronger hydrogen bond interaction with S212 binding site than aromatic fluorine (F) of cobimetinib, which means binimetinib has a higher potency in KRAS-driven cancers than cobimetinib.